Member Info for ajax62

I see Mr Scrabble is back with his CAPITALS doesn't have a clue what's going on. It's only going One way and that up. Close your short if funding lands ?

Break 7p soon buyers coming in must be so confident funding will be sorted. Take no notice of the knobbers that spout s---e

The day is not over yet still time to go higher

Yep.....He is one complete TIT & probably never purchased a share in his life. One complete knobber.

Don't think any of us understand what the mm's do half the time but they certainly play games like they are doing at the moment. Completely oversold this one over the past week so I do expect this going further north this afternoon. GL

Yes noticed the Bid games being played here

Showing as sells LOL

Just being conservative for the short term GT LOL GL

I'm expecting mid 4's for the afternoon session

Back up we go

Put me in a Boxing ring with this PLEB for 60 seconds PLEASE ?

I think Eddie is looking for a 2 bagger on them @ 0.87 That's what I'm looking for so I'll stay with Eddie for a while. GL

Yep @ 3.88 next leg up hopefully

Would love to know the reason why T---S like that get a kick out of going on bulletin boards and ****ging companies off. SAD

Nice start 4p should be gone very soon

Haha.....Remember that post now who posted that one up ? GL

Could be Novartis......They had a breakthrough in August of 2017 but it's just a hunch as there are a few big players out there in the US. One things for sure it's going BLUE today at last. GL

It does say a MAJOR USA Company

Collaboration with major US biotechnology company Tue, 13th Mar 2018 07:00 RNS Number : 4886H Hemogenyx Pharmaceuticals PLC 13 March 2018 � Hemogenyx Pharmaceuticals Plc� ("Hemogenyx" or the "Company") � Collaboration with major US biotechnology company � Collaboration to further�develop humanized mice as a tool for drug development and testing � Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that it has entered into a collaboration with major US biotechnology company in a deal worth up to approximately $250,000 for Hemogenyx. � The collaboration follows on from the announcement made by the Company on 26 February 2018, which confirmed the filing of a provisional patent application relating to the Company's development of a new type of humanized mice with a chimeric mouse-human blood system. These new humanized mice can be used for disease modelling and drug development. � This application of Hemogenyx's humanized mice as a tool for drug development and testing forms the basis of the Company's collaboration with the US biotech company. The collaboration, which is expected to last between four to six months, is a continuation of work previously undertaken in partnership with the company, and has the potential to generate further income as the collaboration develops. � Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "We are pleased to collaborate with a major US biotechnology company, a leader in the field of blood cancer treatment. As we mentioned in our previous announcement, our new type of humanized mice let us extend our work into other disease models and specific drug development. The advancement of this collaboration and potential future collaborations serve both as a validation of our technology and a means of support for the further development of our CDX bi-specific antibody product candidate." � Enquiries: � Hemogenyx Pharmaceuticals Limited www.hemogenyx.com Dr Vladislav Sandler, Chief Executive Officer & Co-Founder Via Walbrook PR Dr Robin Campbell, Chairman Optiva Securities Ltd Tel: +44 (0)20 3137 1902 Christian Dennis� Shard Capital Partners LLP Tel: +44 (0)20 7186 9950 Damon Heath, Erik Woolgar Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey Walbrook PR Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893 � About Hemogenyx Pharmaceuticals Plc Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in Lon

Nice.....So today we move up after a massive retrace...... GL